DK2964229T3 - Benzoimidazol-2-yl-pyrimidinmodulatorer af histamin-h4 receptoren - Google Patents
Benzoimidazol-2-yl-pyrimidinmodulatorer af histamin-h4 receptoren Download PDFInfo
- Publication number
- DK2964229T3 DK2964229T3 DK14760540.6T DK14760540T DK2964229T3 DK 2964229 T3 DK2964229 T3 DK 2964229T3 DK 14760540 T DK14760540 T DK 14760540T DK 2964229 T3 DK2964229 T3 DK 2964229T3
- Authority
- DK
- Denmark
- Prior art keywords
- histamin
- benzoimidazole
- receptor
- modulators
- pyrimidine
- Prior art date
Links
- WTZRQYJHRXQWTK-UHFFFAOYSA-N 2-pyrimidin-2-yl-1h-benzimidazole Chemical compound N=1C2=CC=CC=C2NC=1C1=NC=CC=N1 WTZRQYJHRXQWTK-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/14—Ectoparasiticides, e.g. scabicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/42—Separation; Purification; Stabilisation; Use of additives
- C07C51/43—Separation; Purification; Stabilisation; Use of additives by change of the physical state, e.g. crystallisation
-
- C—CHEMISTRY; METALLURGY
- C30—CRYSTAL GROWTH
- C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
- C30B29/00—Single crystals or homogeneous polycrystalline material with defined structure characterised by the material or by their shape
- C30B29/54—Organic compounds
-
- C—CHEMISTRY; METALLURGY
- C30—CRYSTAL GROWTH
- C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
- C30B7/00—Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions
- C30B7/08—Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions by cooling of the solution
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Virology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- Materials Engineering (AREA)
- Metallurgy (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Ophthalmology & Optometry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Obesity (AREA)
- Communicable Diseases (AREA)
- Cardiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Biotechnology (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361773706P | 2013-03-06 | 2013-03-06 | |
| US201361776260P | 2013-03-11 | 2013-03-11 | |
| US201361784909P | 2013-03-14 | 2013-03-14 | |
| PCT/US2014/021130 WO2014138368A1 (en) | 2013-03-06 | 2014-03-06 | Benzoimidazol-2-yl pyrimidine modulators of the histamine h4 receptor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2964229T3 true DK2964229T3 (da) | 2020-01-27 |
Family
ID=51488591
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK14760540.6T DK2964229T3 (da) | 2013-03-06 | 2014-03-06 | Benzoimidazol-2-yl-pyrimidinmodulatorer af histamin-h4 receptoren |
Country Status (38)
| Country | Link |
|---|---|
| US (4) | US8859575B2 (da) |
| EP (2) | EP2964229B1 (da) |
| JP (1) | JP6471103B2 (da) |
| KR (1) | KR102230383B1 (da) |
| CN (1) | CN105025898B (da) |
| AU (1) | AU2014225675B2 (da) |
| BR (1) | BR112015021463A8 (da) |
| CA (1) | CA2903737C (da) |
| CL (1) | CL2015002434A1 (da) |
| CR (1) | CR20150435A (da) |
| CY (1) | CY1122545T1 (da) |
| DK (1) | DK2964229T3 (da) |
| DO (1) | DOP2016000027A (da) |
| EA (1) | EA201591648A1 (da) |
| ES (1) | ES2773543T3 (da) |
| GT (1) | GT201500243A (da) |
| HR (1) | HRP20200253T1 (da) |
| HU (1) | HUE047681T2 (da) |
| IL (1) | IL240247B (da) |
| JO (1) | JO3516B1 (da) |
| LT (1) | LT2964229T (da) |
| MX (1) | MX373874B (da) |
| MY (1) | MY180726A (da) |
| NZ (1) | NZ710640A (da) |
| PE (1) | PE20151536A1 (da) |
| PH (1) | PH12015501731A1 (da) |
| PL (1) | PL2964229T3 (da) |
| PT (1) | PT2964229T (da) |
| RS (1) | RS59909B1 (da) |
| SA (1) | SA515360981B1 (da) |
| SG (1) | SG11201507117XA (da) |
| SI (1) | SI2964229T1 (da) |
| SM (1) | SMT202000084T1 (da) |
| TW (1) | TWI617554B (da) |
| UA (1) | UA118754C2 (da) |
| UY (1) | UY35370A (da) |
| WO (1) | WO2014138368A1 (da) |
| ZA (1) | ZA201507351B (da) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101460483B (zh) | 2006-03-31 | 2013-05-08 | 詹森药业有限公司 | 作为组胺h4受体调节剂的苯并咪唑-2-基嘧啶和吡嗪 |
| US9371311B2 (en) | 2008-06-30 | 2016-06-21 | Janssen Pharmaceutica Nv | Benzoimidazol-2-yl pyrimidine derivatives |
| NZ710640A (en) | 2013-03-06 | 2019-03-29 | Janssen Pharmaceutica Nv | Benzoimidazol-2-yl pyrimidine modulators of the histamine h4 receptor |
| TWI627174B (zh) | 2013-03-14 | 2018-06-21 | 比利時商健生藥品公司 | Ｐ２ｘ７調控劑 |
| JP6294953B2 (ja) | 2013-03-14 | 2018-03-14 | ヤンセン ファーマシューティカ エヌ．ベー． | Ｐ２ｘ７調節物質 |
| TWI644671B (zh) | 2013-03-14 | 2018-12-21 | 比利時商健生藥品公司 | Ｐ２ｘ７調節劑 |
| WO2014152537A1 (en) | 2013-03-14 | 2014-09-25 | Janssen Pharmaceutica Nv | P2x7 modulators |
| JP6592510B2 (ja) | 2014-09-12 | 2019-10-16 | ヤンセン ファーマシューティカ エヌ．ベー． | Ｐ２ｘ７調節因子 |
| EA201790600A1 (ru) | 2014-09-12 | 2017-07-31 | Янссен Фармацевтика Нв | Модулирующие p2x7 n-ацил-триазолопиразины |
| US20180325931A1 (en) | 2017-01-21 | 2018-11-15 | Ningbo Zhiming Biotechnology Co., Ltd. | Use of paeoniflorin-6'-o-benzenesulfonate in treatment of sjögren's syndrome |
| CN113164459B (zh) | 2018-09-28 | 2024-09-03 | 詹森药业有限公司 | 单酰基甘油脂肪酶调节剂 |
| WO2020065614A1 (en) | 2018-09-28 | 2020-04-02 | Janssen Pharmaceutica Nv | Monoacylglycerol lipase modulators |
| ES3037365T3 (en) | 2019-09-30 | 2025-10-01 | Janssen Pharmaceutica Nv | Radiolabelled mgl pet ligands |
| BR112022019077A2 (pt) | 2020-03-26 | 2022-12-27 | Janssen Pharmaceutica Nv | Moduladores da monoacilglicerol lipase |
Family Cites Families (103)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3005852A (en) | 1959-12-22 | 1961-10-24 | Gen Aniline & Film Corp | Production of sulfoxides and sulfones |
| GB1062357A (en) | 1965-03-23 | 1967-03-22 | Pfizer & Co C | Quinazolone derivatives |
| US3931195A (en) | 1971-03-03 | 1976-01-06 | Mead Johnson & Company | Substituted piperidines |
| US4191828A (en) | 1976-04-14 | 1980-03-04 | Richardson-Merrell Inc. | Process for preparing 2-(2,2-dicyclohexylethyl)piperidine |
| US4337341A (en) | 1976-11-02 | 1982-06-29 | Eli Lilly And Company | 4a-Aryl-octahydro-1H-2-pyrindines |
| US4190601A (en) | 1978-05-31 | 1980-02-26 | Union Carbide Corporation | Production of tertiary amines by reductive alkylation |
| JPS6130576A (ja) | 1984-07-24 | 1986-02-12 | Ube Ind Ltd | ２−アミノ−５−シアノピリミジンの製法 |
| GB9410031D0 (en) | 1994-05-19 | 1994-07-06 | Merck Sharp & Dohme | Therapeutic agents |
| GB9422391D0 (en) | 1994-11-05 | 1995-01-04 | Solvay Interox Ltd | Oxidation of organosulphur compounds |
| JPH10510540A (ja) | 1994-12-12 | 1998-10-13 | オメロス メディカル システムズ，インコーポレーテッド | 灌注用溶液並びに疼痛、炎症及びけいれんの抑制法 |
| CA2249605A1 (en) | 1996-04-03 | 1997-10-09 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| AU715606B2 (en) | 1996-04-03 | 2000-02-03 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| US5880140A (en) | 1996-04-03 | 1999-03-09 | Merck & Co., Inc. | Biheteroaryl inhibitors of farnesyl-protein transferase |
| US5883105A (en) | 1996-04-03 | 1999-03-16 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| US5939439A (en) | 1996-12-30 | 1999-08-17 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| AU5495798A (en) | 1997-01-16 | 1998-08-07 | Sekisui Chemical Co., Ltd. | External preparations for percutaneous absorption |
| CA2277273C (en) | 1997-01-17 | 2008-03-25 | Merck & Co., Inc. | Integrin antagonists |
| US5945422A (en) | 1997-02-05 | 1999-08-31 | Warner-Lambert Company | N-oxides of amino containing pyrido 2,3-D! pyrimidines |
| CA2286239A1 (en) | 1997-04-07 | 1998-10-15 | Merck & Co., Inc. | A method of treating cancer |
| GB9801231D0 (en) | 1997-06-05 | 1998-03-18 | Merck & Co Inc | A method of treating cancer |
| US6399612B1 (en) | 1997-10-06 | 2002-06-04 | Warner-Lambert Company | Heteroaryl butyric acids and their derivatives as inhibitors of matrix metalloproteinases |
| BR9908004A (pt) | 1998-02-17 | 2001-12-18 | Tularik Inc | Composto, composição e método para prevençãoou supressão de uma infecção viral |
| CN1312807A (zh) | 1998-06-19 | 2001-09-12 | 希龙公司 | 糖元合成酶激酶3的抑制剂 |
| EP1038875B1 (en) | 1999-03-25 | 2003-06-04 | Synthon B.V. | Imidazopyridine derivatives and process for making them |
| PT1194425E (pt) | 1999-06-23 | 2005-10-31 | Aventis Pharma Gmbh | Benzimidazoles substituidos |
| TWI279402B (en) | 1999-08-20 | 2007-04-21 | Banyu Pharma Co Ltd | Spiro compounds having NPY antagonistic activities and agents containing the same |
| JP2003510325A (ja) | 1999-09-30 | 2003-03-18 | ニューロジェン・コーポレーション | ある種のアルキレンジアミン−置換ピラゾロ［１，５−ａ］−１，５−ピリミジン及びピラゾロ［１，５−ａ］−１，３，５−トリアジン |
| CA2363274A1 (en) | 1999-12-27 | 2001-07-05 | Japan Tobacco Inc. | Fused-ring compounds and use thereof as drugs for hepatitis c |
| DE10006453A1 (de) | 2000-02-14 | 2001-08-16 | Bayer Ag | Piperidylcarbonsäuren als Integrinantagonisten |
| RU2002131589A (ru) * | 2000-04-24 | 2004-03-27 | Тева Фамэситикл Индастрис Лтд. (Il) | Гемитартрат золпидема |
| ATE335481T1 (de) * | 2000-04-24 | 2006-09-15 | Teva Pharma | Zolpidem hemitartrat solvat |
| AU2001268711A1 (en) | 2000-06-23 | 2002-01-08 | Bristol-Myers Squibb Pharma Company | Heteroaryl-phenyl substituted factor xa inhibitors |
| AU2001289615A1 (en) | 2000-06-28 | 2002-01-08 | Thromb-X N.V. | Pluripotent embryonic stem (es) cell lines, improved methods for their production, and their use for germ line transmission and for the generation of genetically modified animals |
| RU2276142C2 (ru) | 2000-07-21 | 2006-05-10 | Зингента Партисипейшнс Аг | Способ получения 4,6-диметокси-2-метилсульфонилпиримидина (варианты) и применение |
| WO2002020495A2 (en) | 2000-09-06 | 2002-03-14 | Chiron Corporation | Inhibitors of glycogen synthase kinase 3 |
| WO2002042272A2 (en) | 2000-11-20 | 2002-05-30 | Pharmacia Corporation | Substituted polycyclic aryl and heteroaryl pyridines useful for selective inhibition of the coagulation cascade |
| AU2002258400A1 (en) | 2001-02-16 | 2002-08-28 | Tularik Inc. | Methods of using pyrimidine-based antiviral agents |
| US6803362B2 (en) | 2001-03-09 | 2004-10-12 | Ortho-Mcneil Pharmaceutical Inc. | Heterocyclic compounds |
| EP1370250A2 (en) | 2001-03-23 | 2003-12-17 | Chugai Seiyaku Kabushiki Kaisha | Flt-1 ligands and their uses in the treatment of diseases regulatable by angiogenesis |
| JP2004525150A (ja) | 2001-03-30 | 2004-08-19 | スミスクライン ビーチャム コーポレーション | 治療用化合物としてのピラゾロピリジン類の使用 |
| ATE409181T1 (de) | 2001-05-08 | 2008-10-15 | Univ Yale | Proteomimetische verbindungen und verfahren |
| AR035543A1 (es) | 2001-06-26 | 2004-06-16 | Japan Tobacco Inc | Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con |
| DE60213841T2 (de) * | 2001-11-05 | 2007-02-15 | Merck Patent Gmbh | Hydrazono-malonitrile |
| US20030187026A1 (en) | 2001-12-13 | 2003-10-02 | Qun Li | Kinase inhibitors |
| WO2003062235A1 (en) | 2002-01-17 | 2003-07-31 | Eli Lilly And Company | Modulators of acetylcholine receptors |
| TWI270542B (en) | 2002-02-07 | 2007-01-11 | Sumitomo Chemical Co | Method for preparing sulfone or sulfoxide compound |
| US7314937B2 (en) | 2002-03-21 | 2008-01-01 | Eli Lilly And Company | Non-imidazole aryl alkylamines compounds as histamine H3 receptor antagonists, preparation and therapeutic uses |
| ATE425753T1 (de) | 2002-08-02 | 2009-04-15 | Genesoft Pharmaceuticals Inc | Biaryl-verbindungen mit antiinfektiver wirkung |
| EP1543011B1 (en) | 2002-09-06 | 2006-05-03 | Janssen Pharmaceutica N.V. | Thienopyrrolyl and furanopyrrolyl compounds and their use as histamine h4 receptor ligands |
| AU2003274956A1 (en) | 2002-09-06 | 2004-03-29 | Janssen Pharmaceutica, N.V. | Use of indolyl derivatives for the manufacture of a medicament for the treatment allergic rhinitis |
| US20040127395A1 (en) | 2002-09-06 | 2004-07-01 | Desai Pragnya J. | Use of histamine H4 receptor modulators for the treatment of allergy and asthma |
| PL377087A1 (pl) | 2002-09-06 | 2006-01-23 | Janssen Pharmaceutica, N.V. | Związki heterocykliczne |
| WO2004029204A2 (en) | 2002-09-27 | 2004-04-08 | Merck & Co., Inc. | Substituted pyrimidines |
| TW200501960A (en) | 2002-10-02 | 2005-01-16 | Bristol Myers Squibb Co | Synergistic kits and compositions for treating cancer |
| US20040105856A1 (en) | 2002-12-02 | 2004-06-03 | Robin Thurmond | Use of histamine H4 receptor antagonist for the treatment of inflammatory responses |
| CN100372851C (zh) | 2003-05-05 | 2008-03-05 | 弗·哈夫曼-拉罗切有限公司 | 具有crf活性的稠合的嘧啶衍生物 |
| EP1628666B1 (en) | 2003-05-14 | 2015-09-23 | NeuroGenetic Pharmaceuticals, Inc. | Compouds and uses thereof in modulating amyloid beta |
| SE0302116D0 (sv) | 2003-07-21 | 2003-07-21 | Astrazeneca Ab | Novel compounds |
| US20050054663A1 (en) | 2003-08-13 | 2005-03-10 | Bennett Christina N. | GSK-3 inhibitors |
| NZ545864A (en) | 2003-09-22 | 2009-12-24 | S Bio Pte Ltd | Benzimidazole derivates: preparation and pharmaceutical applications |
| EP1670774A1 (en) | 2003-09-30 | 2006-06-21 | Janssen Pharmaceutica N.V. | Quinoxaline compounds |
| AR045955A1 (es) | 2003-09-30 | 2005-11-16 | Janssen Pharmaceutica Nv | Compuestos benzoimidazolicos |
| WO2005032490A2 (en) | 2003-10-08 | 2005-04-14 | Bristol-Myers Squibb Company | Cyclic diamines and derivatives as factor xa inhibitors |
| WO2005040135A1 (ja) | 2003-10-24 | 2005-05-06 | Ono Pharmaceutical Co., Ltd. | 抗ストレス薬およびその医薬用途 |
| US8277831B2 (en) | 2004-02-17 | 2012-10-02 | Advanced Technologies And Regenerative Medicine, Llc. | Drug-enhanced adhesion prevention |
| MXPA06011021A (es) | 2004-03-25 | 2007-04-13 | Johnson & Johnson | Compuestos de imidazol. |
| WO2005115993A1 (ja) | 2004-05-31 | 2005-12-08 | Banyu Pharmaceutical Co., Ltd. | キナゾリン誘導体 |
| CA2572218C (en) | 2004-06-30 | 2013-06-11 | Janssen Pharmaceutica, N.V. | Aryl-substituted benzimidazole and imidazopyridine ethers as anti-cancer agents |
| AU2005278292B2 (en) | 2004-08-31 | 2011-09-08 | Msd K.K. | Novel substituted imidazole derivatives |
| US7906528B2 (en) | 2004-10-05 | 2011-03-15 | Novartis International Pharmaceutical Ltd. | Pyrrolo-pyridine, pyrrolo-pyrimidine and related heterocyclic compounds |
| US7381732B2 (en) | 2004-10-26 | 2008-06-03 | Bristol-Myers Squibb Company | Pyrazolobenzamides and derivatives as factor Xa inhibitors |
| AU2005316091B2 (en) | 2004-12-17 | 2011-12-01 | Merck Canada Inc. | 2-(phenyl or heterocyclic)-1H-phenantrho[9,10-D]imidazoles as mPGES-1 inhibitors |
| US7442716B2 (en) | 2004-12-17 | 2008-10-28 | Merck Frosst Canada Ltd. | 2-(phenyl or heterocyclic)-1H-phenantrho[9,10-d]imidazoles as mPGES-1 inhibitors |
| EP1863756A1 (en) | 2005-03-24 | 2007-12-12 | Janssen Pharmaceutica N.V. | Biaryl derived amide modulators of vanilloid vr1 receptor |
| WO2007044085A2 (en) | 2005-05-19 | 2007-04-19 | Xenon Pharmaceuticals Inc. | Heteroaryl compounds and their uses as therapeutic agents |
| EA015890B1 (ru) | 2005-06-14 | 2011-12-30 | Тайджен Байотекнолоджи Ко. Лтд. | Производные пиримидина |
| US8193206B2 (en) | 2005-06-14 | 2012-06-05 | Taigen Biotechnology Co., Ltd. | Pyrimidine compounds |
| MX2007015675A (es) | 2005-07-04 | 2008-02-20 | Novo Nordisk As | Antagonistas del receptor de histamina h3. |
| WO2007031529A1 (en) | 2005-09-13 | 2007-03-22 | Palau Pharma, S.A. | 2-aminopyrimidine derivatives as modulators of the histamine h4 receptor activity |
| AR056560A1 (es) | 2005-10-06 | 2007-10-10 | Astrazeneca Ab | Pirrolopiridinonas como moduladores cb1 |
| CA2627722A1 (en) | 2005-10-31 | 2007-06-21 | Merck & Co., Inc. | Cetp inhibitors |
| US20090182142A1 (en) | 2005-12-02 | 2009-07-16 | Shigeru Furukubo | Aromatic Compound |
| EP1989187A4 (en) | 2006-02-24 | 2009-07-08 | Merck Frosst Canada Ltd | 2- (PHENYL OR HETEROCYCLYL) -1H-PHENANTHRO (9,10-D) IMIDAZOLE |
| CN101460483B (zh) | 2006-03-31 | 2013-05-08 | 詹森药业有限公司 | 作为组胺h4受体调节剂的苯并咪唑-2-基嘧啶和吡嗪 |
| WO2007117400A2 (en) | 2006-03-31 | 2007-10-18 | Janssen Pharmaceutica N.V. | Benzoimidazol-2-yl pyridines as modulators of the histamine h4 receptor |
| US7544698B2 (en) | 2006-04-07 | 2009-06-09 | Janssen Pharmaceutica, N.V. | Indoles and benzoimidazoles as modulators of the histamine H4 receptor |
| EP2010177A2 (en) | 2006-04-10 | 2009-01-07 | Janssen Pharmaceutica N.V. | Combination histamine h1r and h4r antagonist therapy for treating pruritus |
| EP2019675A4 (en) | 2006-05-02 | 2011-03-02 | Merck Frosst Canada Ltd | METHOD FOR THE TREATMENT OR PREVENTION OF NEOPLASIA |
| CA2652238A1 (en) | 2006-05-18 | 2007-11-29 | Merck Frosst Canada Ltd. | Phenanthrene derivatives as mpges-1 inhibitors |
| EP2040549B1 (en) | 2006-07-11 | 2013-10-23 | Janssen Pharmaceutica NV | Benzofuro-and benzothienopyryimidine modulators of the histamine h4 receptor |
| US8779154B2 (en) * | 2006-09-26 | 2014-07-15 | Qinglin Che | Fused ring compounds for inflammation and immune-related uses |
| TW200904437A (en) | 2007-02-14 | 2009-02-01 | Janssen Pharmaceutica Nv | 2-aminopyrimidine modulators of the histamine H4 receptor |
| PE20091035A1 (es) | 2007-11-30 | 2009-07-16 | Palau Pharma Sa | Derivados de 2-aminopirimidina |
| WO2009079001A1 (en) | 2007-12-18 | 2009-06-25 | Janssen Pharmaceutica N.V. | Bicyclic heteroaryl-substituted imidazoles as modulators of the histamine h4 receptor |
| EA019143B1 (ru) | 2008-06-12 | 2014-01-30 | Янссен Фармацевтика Нв | Использование антагонистов н4-гистаминовых рецепторов для лечения послеоперационных спаек |
| CN102118969B (zh) | 2008-06-12 | 2017-03-08 | 詹森药业有限公司 | 组胺h4受体的二氨基吡啶、二氨基嘧啶和二氨基哒嗪调节剂 |
| EP2924023A1 (en) | 2008-06-30 | 2015-09-30 | Janssen Pharmaceutica NV | piperidine und piperazine derivativs |
| CN103319459A (zh) | 2008-06-30 | 2013-09-25 | 詹森药业有限公司 | 用于制备苯并咪唑-2-基嘧啶衍生物的方法 |
| US8852569B2 (en) * | 2008-08-28 | 2014-10-07 | The General Hospital Corporation | Prevention and treatment of itch with cysteine protease inhibition |
| IT1395963B1 (it) * | 2009-06-04 | 2012-11-02 | Rottapharm Spa | Forme cristalline di 6-(1h-imidazol-1-il)-2-fenil chinazolina e dei suoi sali |
| TWI519533B (zh) | 2010-11-01 | 2016-02-01 | Ｌｇ生命科學有限公司 | １－｛（２Ｓ）－２－胺基－４－［２，４－雙（三氟甲基）－５，８－二氫吡啶并［３，４－ｄ］嘧啶－７（６Ｈ）－基］－４－側氧丁基｝－５，５－二氟哌啶－２－酮酒石酸鹽之水合物 |
| EP2465498A1 (en) | 2010-11-23 | 2012-06-20 | Faes Farma, S.A. | Diphenyl-amine derivatives: uses, process of synthesis and pharmaceutical compositions |
| NZ710640A (en) | 2013-03-06 | 2019-03-29 | Janssen Pharmaceutica Nv | Benzoimidazol-2-yl pyrimidine modulators of the histamine h4 receptor |
-
2014
- 2014-03-06 NZ NZ710640A patent/NZ710640A/en not_active IP Right Cessation
- 2014-03-06 HR HRP20200253TT patent/HRP20200253T1/hr unknown
- 2014-03-06 JO JOP/2014/0074A patent/JO3516B1/ar active
- 2014-03-06 SG SG11201507117XA patent/SG11201507117XA/en unknown
- 2014-03-06 DK DK14760540.6T patent/DK2964229T3/da active
- 2014-03-06 MX MX2015011688A patent/MX373874B/es active IP Right Grant
- 2014-03-06 ES ES14760540T patent/ES2773543T3/es active Active
- 2014-03-06 US US14/199,634 patent/US8859575B2/en active Active
- 2014-03-06 LT LTEP14760540.6T patent/LT2964229T/lt unknown
- 2014-03-06 SI SI201431440T patent/SI2964229T1/sl unknown
- 2014-03-06 EP EP14760540.6A patent/EP2964229B1/en active Active
- 2014-03-06 JP JP2015561646A patent/JP6471103B2/ja not_active Expired - Fee Related
- 2014-03-06 BR BR112015021463A patent/BR112015021463A8/pt not_active Application Discontinuation
- 2014-03-06 PL PL14760540T patent/PL2964229T3/pl unknown
- 2014-03-06 RS RS20200160A patent/RS59909B1/sr unknown
- 2014-03-06 WO PCT/US2014/021130 patent/WO2014138368A1/en not_active Ceased
- 2014-03-06 PE PE2015001832A patent/PE20151536A1/es not_active Application Discontinuation
- 2014-03-06 AU AU2014225675A patent/AU2014225675B2/en not_active Ceased
- 2014-03-06 CA CA2903737A patent/CA2903737C/en active Active
- 2014-03-06 KR KR1020157026804A patent/KR102230383B1/ko not_active Expired - Fee Related
- 2014-03-06 HU HUE14760540A patent/HUE047681T2/hu unknown
- 2014-03-06 UY UY0001035370A patent/UY35370A/es unknown
- 2014-03-06 EA EA201591648A patent/EA201591648A1/ru unknown
- 2014-03-06 TW TW103107723A patent/TWI617554B/zh not_active IP Right Cessation
- 2014-03-06 MY MYPI2015702907A patent/MY180726A/en unknown
- 2014-03-06 PT PT147605406T patent/PT2964229T/pt unknown
- 2014-03-06 EP EP19213615.8A patent/EP3660011A1/en not_active Withdrawn
- 2014-03-06 CN CN201480012369.2A patent/CN105025898B/zh not_active Expired - Fee Related
- 2014-03-06 SM SM20200084T patent/SMT202000084T1/it unknown
- 2014-06-03 UA UAA201509634A patent/UA118754C2/uk unknown
- 2014-08-21 US US14/465,677 patent/US9278952B2/en not_active Expired - Fee Related
-
2015
- 2015-07-30 IL IL240247A patent/IL240247B/en active IP Right Grant
- 2015-08-06 PH PH12015501731A patent/PH12015501731A1/en unknown
- 2015-08-24 CR CR20150435A patent/CR20150435A/es unknown
- 2015-08-31 CL CL2015002434A patent/CL2015002434A1/es unknown
- 2015-09-02 GT GT201500243A patent/GT201500243A/es unknown
- 2015-09-03 SA SA515360981A patent/SA515360981B1/ar unknown
- 2015-10-05 ZA ZA2015/07351A patent/ZA201507351B/en unknown
-
2016
- 2016-01-22 DO DO2016000027A patent/DOP2016000027A/es unknown
- 2016-02-18 US US15/047,359 patent/US9434715B2/en not_active Expired - Fee Related
- 2016-08-03 US US15/227,878 patent/US9663497B2/en not_active Expired - Fee Related
-
2020
- 2020-02-03 CY CY20201100085T patent/CY1122545T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2964229T3 (da) | Benzoimidazol-2-yl-pyrimidinmodulatorer af histamin-h4 receptoren | |
| IL245848B (en) | Octahydro fused azadecalin glucocorticoid receptor modulators | |
| DK3395814T3 (da) | Hæmmere af fibroblastvækstfaktorreceptoren | |
| DK2970954T3 (da) | Modifikation af polypeptider | |
| DK3087183T3 (da) | Modulation af angiopoietin-3-lignende ekspression | |
| DK2845905T3 (da) | Fremstilling af oligosaccharider | |
| HRP20182004T1 (hr) | Tetrahidropiridopirazini modulatori gpr6 | |
| HUE049794T2 (hu) | Új aminopirimidin származékok | |
| DK3300500T3 (da) | Triazolagonister af apj-receptoren | |
| DK2954051T3 (da) | Modificeret kapsid til genoverførsel til behandling af nethinden | |
| EP2972579A4 (en) | DIGITAL REGULATION OF THE EYE DISTANCE | |
| DK2981255T3 (da) | Terapeutiske anvendelser af empagliflozin | |
| DK3083540T3 (da) | Fremgangsmåde til fremstilling af substituerede phenoxyphenylketoner | |
| DK2961388T3 (da) | Kombinationer af lægemidler | |
| EP2964120A4 (en) | ILIAKALVERBINDER | |
| PL2928870T3 (pl) | Ligandy receptora neurotensyny | |
| SMT201700009B (it) | Modulatori del recettore x del fegato | |
| DK3010895T3 (da) | Fremgangsmåde til fremstilling af 4-propargyleret aminobenzoxazinoner | |
| DK2965026T3 (da) | Generering af slushice | |
| SMT201600374B (it) | Modulatori del recettore x del fegato | |
| EP3042244A4 (en) | TONER | |
| DK2991543T3 (da) | System til visualisering af kropsområder | |
| UA27558S (uk) | Лінза | |
| DK3052931T3 (da) | Fremgangsmåde til overførsel af opslæmning | |
| DK3082642T3 (da) | Fiksering af protesetænder |